Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α<i>‐</i>positive ovarian cancer: Justification of therapeutic dose regimen
The trough concentration of MIRV correlated with efficacy whereas the AUC of MIRV was associated with major AEs. The ER relationships supported the selected therapeutic dose regimen.
Authors
- Michael Method
- Eric H. Westin (ORCID: https://orcid.org/0000-0003-0882-6782)
- Timothy Parrott
- Yuemei Wang
- H. Maxime Lagraauw (ORCID: https://orcid.org/0000-0002-5118-4247)
- Eva Hanze (ORCID: https://orcid.org/0009-0001-4926-1792)
- Callum M. Sloss
- Ya‐Ping Tu (ORCID: https://orcid.org/0000-0001-5564-9358)
- Lingling Li (ORCID: https://orcid.org/0000-0003-4596-8712)
Institutions
- ImmunoGen (United States) (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-09-22
- DOI
- https://doi.org/10.1111/bcp.16250
- Citations
- 7
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.76